Snapshot · Eli Lilly and Company (LLY)

Data as of 2026-09-01T23:18:44.518Z

Fundamentals check

Market cap

$1.09T

P/E (TTM)

38.9

Gross margin

84.0%

Net margin

33.5%

ROE

92.6%

R&D / revenue

18.3%

Dividend yield

0.6%

FCF yield

1.8%

Latest dividend: $1.73/share (ex-date 2026-08-14, quarterly)

Summary

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

How it makes money

Revenue mix, latest fiscal year

• Product93.5%
• Collaboration and Other Revenue6.5%

Recent Events

• 2026-08-31T06:53:18.000Zpositive

  Eli Lilly to buy Merida Biosciences in $2.88 billion deal

  恰逢公司扩大免疫学管线的并购行动，或有助于长期增长，但并购影响需视整合情况。

  Source: reuters.com

• 2026-08-28T07:00:00.000Zpositive

  FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes

  可能与Mounjaro扩展适用人群相关，提升分析师对长期CV益处的预期，实际影响需关注上市后证据。

  Source: prnewswire.com

• 2026-08-26T14:59:00.000Zpositive

  Eli Lilly Clears Big Hurdle in Alzheimer's Fight

  可能与与Roche联合开发的血液检测取得进展相关，事件增添积极情绪，尚需看到长期效应。

  Source: gurufocus.com

• 2026-08-24T07:56:57.000Zpositive

  Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance

  可能与公司在阿尔茨海默病诊断领域的推进相关，FDA清除显示进展，但因广泛临床意义仍有不确定性。

  Source: reuters.com

• 2026-08-19T00:00:00.000Zpositive

  Price move: LLY rose 4.5%

  LLY 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-05T00:00:00.000Zneutral

  LLY filed 10-Q

  恰逢公司披露季度信息，短期波动可能由公告驱动，但因内容未知，因果性需谨慎判断。

  Source: SEC EDGAR

• 2026-08-05T00:00:00.000Zpositive

  Price move: LLY rose 4.9%

  LLY 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-06-26T00:00:00.000Zpositive

  Price move: LLY rose 7.1%

  LLY 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-06-04T00:00:00.000Zpositive

  Price move: LLY rose 4.3%

  LLY 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

Analyst view

Avg price target $1354.5 from 16 analysts (last quarter)

Insider & Congress activity

Open-market trades only; grants and exercises excluded

• 2026-08-17SellJonsson Patrik(officer: EVP & President, LLY Int'l)6,500 shares
• 2026-08-10SellZakrowski Donald A(officer: SVP, Finance, & CAO)2,000 shares
• 2026-08-07SellHakim Anat(officer: EVP, GC & Secretary)5,000 shares
• 2026-06-10SellYuffa Ilya(officer: EVP&Pres, LLY USA&Global Capab)2,500 shares

订阅每日简报

每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。

本内容仅为信息整理，不构成任何投资建议。